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B R I E F R E P O R T
Estimating the Impact of Human
Papillomavirus (HPV) Vaccination
on HPV Prevalence and Cervical
Cancer Incidence in Mali
LaRee Tracy,1 Holly D. Gaff,4 Colleen Burgess,5 Samba Sow,2,6 Patti
E. Gravitt,3 and J. Kathleen Tracy1
Departments of 1Epidemiology and Public Health and 2Medicine, Center for Vaccine
Development, University of Maryland School of Medicine and 3Johns Hopkins
Bloomberg School of Public Health, Department of Epidemiology, Johns Hopkins
University, Baltimore, Maryland; 4Old Dominion University, Norfolk, Virginia;
5Math Ecology, Phoenix, Arizona; and 6Centre Pour Le Developpement Des Vaccins,
Bamako, Mali
Human papillomavirus vaccines have potential to reduce
cervical cancer incidence and mortality; however, cultural
and economic barriers may hinder success in developing
countries. We assessed impact of a single vaccine campaign
in Mali with use of mathematical modeling. Our model
shows that decreases in the prevalence of Human papillo-
mavirus infection are proportional to achieved vaccination
coverage.
Persistent infection with certain viral strains of human papil-
lomavirus (HPV) is a necessary cause of cervical cancer [1].
Licensed vaccines to prevent cervical cancer represent a signifi-
cant public health breakthrough that may benefit women
worldwide; however, this will only be realized if vaccines are
delivered to populations in greatest need. Developing countries
bear the greatest cervical cancer burden, with 80% of cervical
cancer–associated deaths [2] but are least likely to benefit from
HPV vaccines owing to limited resources necessary for acquiring
and delivering the 3-dose regimen. In addition, vaccinating
women before sexual debut is especially challenging in sub-Sa-
haran Africa [3] because of limited health care funding, rare
reproductive health services, and dispersed populations. Some
estimates suggest that HPV vaccines will be feasible in countries
with low socioeconomic status (ie, gross domestic product
,US$1000 per capita) only if the per-dose cost is reduced to
US$1–2 [4].
Mali is a landlocked sub-Saharan West African country with
an estimated 12.3 million persons [5, 6]. Cervical cancer is the
most common cancer among Malian women, with an annual
age-adjusted incidence rate of 35.2 cases per 100,000 pop-
ulation [2]; it is also the leading cause of cancer-related mor-
tality. Because of economic and infrastructure challenges, no
organized cervical cancer screening programs exist in Mali.
Because Mali is one of the countries with the lowest socio-
economic status [7], resources to implement a vaccination
program are lacking; most implemented vaccination programs
are subsidized by external organizations. Despite available
vaccines (eg, Gardasil Access program), challenges in im-
plementing vaccines remain owing to widely dispersed pop-
ulations and limited infrastructure to support a multidose
vaccination campaign. Consequently, it is a public health ne-
cessity to evaluate probable impacts of a vaccination program
during pre-implementation planning.
HPV mathematical models exist; however, none directly
apply to developing countries. Previous models focus almost
exclusively on developed countries [8–11]. Demographic,
cultural, and economic differences among countries along the
economic development continuum imply that existing models
will not provide necessary estimates and insight for planning
and implementation of an effective vaccination program in
a country such as Mali. For example, the model for HPV
transmissibility developed by Burchell et al [8] was based on
a university sample of unmarried and uncircumcised individuals
able to form multiple sexual partnerships. In contrast, the female
Malian population has an 89% probability of being circumcised
(a known risk factor for cervical cancer [12]) and marries at an
earlier age; nearly half are in a polygamous marriage. These
factors, which might affect successful implementation of any
HPV vaccination program, formed the basis of our mathematical
models exploring the probable impact of HPV vaccination in
Mali.
Purpose
To use mathematical models to evaluate the impact of a single
vaccination campaign of all at-risk female individuals in Mali.
We focused on common HPV types 16 and 18, which
collectively account for 70% of cervical cancer cases world-
wide [13–15].
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METHODS
Model
We developed a deterministic mathematical model to evaluate the
impact of vaccination and sexual mixing on predicted prevalence
of HPV infection and cervical cancer incidence. This model of
heterosexual HPV transmission dynamics followed developed
models [16], dividing the population into 3 sexual activity and/or
risk groups defined by differences in partner change rate.
Vaccination Strategies
Focusing on the at-risk Mali population (women aged >11
years), we assessed vaccine coverage rates of 0%, 15%, 30%,
50%, and 90%, corresponding to 1, 2, 3, and 5.5 million
vaccine doses.
Sexual Mixing Patterns
Risk of HPV infection in susceptible women varies with age and
sexual activity risk group, reflecting known heterogeneity in risk
for acquiring sexually transmitted infections. Once infected, cer-
vical cancer risk increases with duration of infection. Risk groups
reflect low, medium, and high numbers of annual sexual partners
and are proportional to HPV transmission risk. Sexual mixing
data for the Malian population are lacking; therefore, we assessed
random, partially assortative, and fully assortative mixing patterns.
Random mixing assumes that individuals select sexual partners
from all risk groups with equal probability; fully assortative
implies partner selection in only the same risk group, whereas
partially assortative represents a hybrid of partners selection with
preference to partners from the same risk group [17, 18].
Study Population
The model population was based on 2007 Mali data comprising
12.3 million persons with a mean life expectancy of 50 years [5]
(Table 1).
Parameter Estimates
Table 2 provides default values for Mali-specific parameters in
the model, assuming that cervical carcinogenesis is similar for
various populations. Parameters were derived from published
literature and unpublished pilot research conducted by the
senior author (JKT) that estimated local prevalence of high-risk
HPV infection and assessed HPV infection risk factors in Malian
women. Results from this pilot study suggest that 12% ofMalian
women had a prevalent infection with a cancer-causing HPV
strain.
RESULTS
Results show increasing vaccination coverage significantly de-
creases total prevalence of HPV infection. For example, 15%
vaccination coverage reduces the maximum prevalence of in-
fection from 39% to 33%, whereas 90% coverage reduces the
peak prevalence to 7% (Table 3). We explored the effect of
different vaccination strategies on cervical cancer burden by
modeling numbers of women predicted to have persistent HPV
infection that could lead to cervical cancer (ie, women with
disease) for each vaccination strategy. Figure 1 shows women
with disease, by risk group, for each vaccination strategy,
showing reductions in total numbers of women with disease
proportional to vaccination coverage. Without vaccination, the
25-year cumulative incidence of cervical cancer is 27 cases per
1000 persons, compared with 3 cases per 1000 persons with
90% coverage, corresponding to a relative reduction of 89%
(Table 4).
Simulations assuming randommixing predicted the highest
total prevalence of HPV infection, whereas fully assortative
mixing predicted the lowest prevalence for all vaccination
strategies. However, with 90% coverage, the negative effect of
random mixing is negligible. In addition, the benefits of fully
assortative mixing are not equal across risk groups. The
greatest benefit occurs in the lowest risk group, whereas in the
highest risk group, which includes pairing with other
individuals at high risk, the model predicted a higher
prevalence.
DISCUSSION
HPV vaccines offer an innovative strategy for cervical cancer
control and prevention; however, knowledge of the real world
impact of these vaccines remains in its infancy. Published
Table 1. Mali Population Estimates, by Risk Group
Population Size in 2007 [28], no. (%) Prevalence/person [28] No. Infected at T0 No. Susceptible at T0
Risk Group,
age, years Male Females Male Female Male Female Male Female
,15 3,320,765 (0.531) 3,198,961 (0.519) 0.0001 0.0001 332 320 3,320,433 3,198,641
15–24 1,393,195 (0.223) 1,353,382 (0.219) 0.17 0.17 236,843 230,075 1,156,352 1,123,307
25–50 1,540,562 (0.246) 1,616,803 (0.262) 0.3 0.15 462,169 242,520 1,078,393 1,374,283
All 6,254,522 6,169,146 699,344 472,915 5,555,178 5,696,231
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mathematical models are based on theoretical assumptions us-
ing data prior to vaccine licensures and almost exclusively in-
cluded parameter estimates derived from data for developed
countries. Thus, the impact of HPV vaccination in developing
countries is unknown. Using Mali-specific assumptions and
parameter values, we assessed the impact of several single vac-
cination scenarios on HPV infection. Our findings suggest that
reduction in peak prevalence of high-risk HPV infection is di-
rectly proportional to vaccination coverage, with the maximum
reduction of 82% in peak prevalence with 90% coverage.
We explored the impact of vaccination strategies on cervical
cancer burden by tracking numbers of women predicted to
have persistent high-risk HPV infection that could lead to cer-
vical cancer. Similar to our findings of vaccination effect on
peak prevalence, reductions in numbers of women with disease
were observed for each risk group with increasing vaccination
coverage, with a relative reduction of up to 89% at 90% coverage
Finally, our models predicted that, for all coverage scenarios,
random sexual mixing patterns resulted in the highest total
prevalence of HPV infection, and fully assortative mixing
resulted in the lowest peak prevalence, although the negative
effect of random sexual mixing is negligible with 90% coverage.
Furthermore, the benefits of fully assortative mixing are not
uniform across risk groups.
Similar to other studies [16], our models suggest that pop-
ulation and vaccine program characteristics affect prevalence of
HPV infection and prevalence of persistent HPV infection. Diaz
et al [19] modeled the impact of HPV vaccination on cervical
cancer prevention in India, reporting a 44% reduction with 70%
vaccination coverage. In contrast, we focused on reduction in
HPV infection, as the first step in the carcinogenesis pathway,
and estimated a relative reduction in prevalence of HPV in-
fection approaching 50%with 50% coverage. Our analyses reveal
the importance of country- and culturally specific parameters,
Table 2. Model Parametersa
Model Parameters Parameter Value(s) Source
Female individuals
Proportion vaccinated /f [0,1] Assumed
Annual cervical cancer rate s 0.01 Bayo et al [12]
Annual cervical cancer mortality rate
(age standardized)
Ca_D 28.4 deaths/100,000 population WHO HPV and CC
summary report, 2007(28)
Probability of HPV transmission from
infected man
bf 0.8
Men
Proportion vaccinated /m [0,1] Assumed
Probability of HPV transmission from
infected female
bm 0.7
Both sexes
Annual mean duration in risk group 1/u [10 10 15]
Proportion in risk group x [.53 .22 .25]
Annual sexual partners p [.7 5.2 10.1]
Annual mortality rate (background) d 0.016 CIA Fact book [5]
Mixing parameter e [0 1] Assumed
Duration of infectiousness 1/c 0.15 Hughes et al [16] (29–31)
a Risk group 1: ,15 years; risk group 2: 15–24 years; risk group 3: .25 years.
Table 3. Comparison of Reduction in Prevalence for 4 Vaccine Scenarios, Compared with No Vaccine
Scenario, coverage
Peak
Prevalence, %
Absolute reduction in prevalence,
compared with no vaccine, %
Relative reduction in prevalence,
compared with no vaccine, %
None 39 0 .
15% 33 6 15
30% 28 11 28
50% 20 19 49
90% 7 32 82
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which differ across populations, to evaluate the probable impact
of vaccine implementation.
HPV vaccines are designed to prevent cancer associated with
viral infection; however, the long-term value of these vaccines is
tempered by several critical issues. First, although current vac-
cines target the HPV strains that account for 70% of cervical
cancers worldwide, other cancer-causing strains circulate in the
population and require continued screening. [20]. Second,
vaccinating young women before HPV exposure (ideally before
their sexual debut) presents unique economic, cultural, and
logistical challenges.
Mathematical models of HPV infection are inherently
limited by the extant knowledge and understanding of HPV
infection. The simulations reported here include relevant
parameters previously defined for models of developed
countries. Future studies will explore culture-specific factors
influencing this dynamic process, interactions between HPV
strains, and vaccine cost-effectiveness in developing countries.
Our research and future analyses can guide implementation of
HPV vaccination in resource-poor settings to effectively
reduce total burden of HPV infection and cervical cancer–
related deaths.
Table 4. Reduction in Cumulative Incidence of Cervical Cancer at 25 Years, Compared with No Vaccine
Variable
Vaccination Coverage
0% 15% 30% 50% 90%
Cumulative Incidence at 25 years/person 0.027 0.023 0.018 0.013 0.003
Absolute Reduction in Cumulative Incidence/person, % . 0.4 0.9 1.4 2.4
Relative Reduction in Cumulative Incidence/person, % . 14.8 33.3 51.8 88.9
Figure 1. Prevalence of persistent human papilloma virus (HPV) infection, by risk group, for each vaccination strategy.
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